Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  SIX SWISS EXCHANGE AG  >  Roche Holding Ltd.       CH0012032048

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( CHF)
Sales 2017 53 372 M
EBIT 2017 18 682 M
Net income 2017 11 547 M
Debt 2017 8 750 M
Yield 2017 3,22%
Sales 2018 56 250 M
EBIT 2018 20 107 M
Net income 2018 12 803 M
Debt 2018 3 030 M
Yield 2018 3,44%
P/E ratio 2017 19,48
P/E ratio 2018 17,78
EV / Sales2017 4,48x
EV / Sales2018 4,15x
Capitalization 230 451 M
More Financials
Company
Roche Holding AG operates as a research healthcare company.It operates through the following segments: Diagnostics and Pharmaceuticals.The pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience.The... 
Sector
Pharmaceuticals
Calendar
05/31Presentation
More about the company
Surperformance© ratings of Roche Holding Ltd.
Trading Rating : Investor Rating :
More Ratings
Latest news on ROCHE HOLDING LTD.
05/26 ROCHE : U.S. Patents Awarded to Inventors in New Jersey (May 26)
05/26 PFIZER : FDA advisers back Puma breast cancer drug despite safety worries
05/25 FOUNDATION MEDICINE : and Its Collaborators to Present New Data at ASCO 2017 Sup..
05/25 CHUGAI PHARMACEUTICAL : Findings on Immunoglobulins Detailed by Researchers at C..
05/25 ROCHE : Lethal brain infection in German MS patient prompts Roche investigation
05/24 ROCHE : receives FDA approval for complementary PD-L1 (SP263) biomarker test
05/24 Freeze Drying Agenda Released for Lyophilization USA 2017
05/24 ROCHE : New data at ATS add to the body of evidence for Roche’s Esbriet (p..
05/23 ROCHE : Presolicitation Notice - Roche MagNA Pure 96 Instrument IVD
05/23 BIOLINERX : Announces Regulatory Submission for Phase 1b Trial of BL-8040 in Com..
More news
Sector news : Pharmaceuticals - NEC
05/26DJSUN PHARMACEUTICAL INDUSTRIES : Pharma 4Q Profit Falls 13.6%
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
More sector news : Pharmaceuticals - NEC
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 289  CHF
Spread / Average Target 8,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.236 581
JOHNSON & JOHNSON10.69%341 901
ROCHE HOLDING LTD.14.88%236 581
NOVARTIS AG6.75%211 457
PFIZER INC.-1.05%191 398
MERCK & CO., INC.10.28%177 567
More Results